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Abstract
OBJECTIVES: Restaging of patients with locally advanced non-small-cell lung cancer (NSCLC) is of paramount importance, since only
patients with down-staging after induction therapy will beneﬁt from surgery. In this study, we assessed the aetiology of new 18ﬂuoro-2-
deoxy-D-glucose (FDG)-positive focal abnormalities on restaging positron emission tomography/computed tomography (PET/CT) in
patients with a good response after induction chemotherapy in the primary tumour and lymph nodes.
METHODS: Between 2004 and 2008, 31 patients with histological proven stage III NSCLC had a PET/CT prior and after induction
chemotherapy. Their medical charts were retrospectively reviewed.
RESULTS: Restaging PET/CT revealed a new FDG-positive lesion in 6 of 31 (20%) patients. The initial clinical stage of the disease was
IIIA N2 in four and IIIB T4 in two patients. The maximal standard uptake value in the primary tumour (P = 0.043) and in the initially
involved mediastinal nodes (P = 0.068) decreased after induction treatment in all patients. The new PET/CT ﬁndings were located in an
ipsilateral cervical lymph node in two patients, a contralateral mediastinal in one patient and an ipsilateral mammary internal lymph
node in one patient. Two other patients had a lesion on the contralateral lung. Malignant lymph node inﬁltrations were excluded fol-
lowing ﬁne-needle puncture, intraoperative biopsy or follow-up PET/CT. Contralateral pulmonary lesions were diagnosed as benign fol-
lowing mini thoracotomy and pulmonary wedge resection.
CONCLUSIONS: New solitary FDG-positive lesions on restaging PET/CT after induction chemotherapy for NSCLC are not rare in good
responders to chemotherapy. In our experience, all these lesions were not associated with malignancy.
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INTRODUCTION
Patients with clinical stage III-N2 or -T4 non-small-cell lung
cancer (NSCLC) have a poor prognosis when treated with surgery
alone. In order to improve outcome, the concept of preoperative
induction therapy was introduced. It has been shown that
induction chemotherapy (or radiochemotherapy) combined with
surgery is effective in selected subgroups of patients such as
patients with IIIA-N2 disease [1, 2]. Recent studies suggested that
mediastinal down-staging and complete resection after induction
are signiﬁcant factors for better outcome in cases of stage IIIA or
IIIB disease. But several reports have also described an increased
perioperative morbidity and mortality for surgical resection
following induction therapy compared with resection without
induction treatment [3]. Therefore, restaging after induction
therapy plays a central role in selecting candidates for resection.
18Fluoro-2-deoxy-D-glucose positron-emission tomography
with integrated computed tomography (FDG-PET/CT) has
become widely adopted as a major tool for the staging of
NSCLC and has been increasingly incorporated into the routine
work-up for restaging after induction therapy. However, due to
poor sensitivity of 50–60%, PET scan for mediastinal restaging is
not as accurate as prior to induction [4–8].
In this study, we assessed the signiﬁcance of new solitary
FDG-positive lesions on restaging PET/CT located in lymph
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nodes or in the contralateral lung in patients who showed a
good radiological response in the primary tumour and in the
mediastinal nodes after induction therapy.
MATERIALS AND METHODS
Between January 2004 and March 2008, an integrated whole-
body PET/CT was carried out on a consecutive series of 603
patients with potentially operable NSCLC. Conventional staging
by means of a history, physical ﬁndings, blood test, bronchos-
copy and contrast medium-enhanced CT scan of the chest and
upper abdomen was carried out in all patients. A hundred and
forty-ﬁve (24%) of these patients with clinical stage III disease
underwent induction chemotherapy or radiochemotherapy.
Restaging was carried out by use of CT scan. Patients without
evidence of disease progression after restaging underwent
surgery. Anatomical resection of the primary tumour combined
with a mediastinal lymph node dissection was carried out when-
ever possible according to the lung function test after induction
and to the intraoperative ﬁndings.
In 31 patients, additional restaging PET/CT was carried out 4
weeks after induction therapy. Stage IIIA was observed in 26
patients and stage IIIB in 5 patients. Stage IIIA included T1N2,
T2N2, T3N1 and T3N2 in 2, 16, 1 and 7 patients, respectively,
whereas stage IIIB included T4N0, T4N1 and T4N2 in 1, 2 and 2
patients. In patients with stage IIIA N2, suspected tumour in-
volvement of the mediastinal lymph nodes on PET/CT had been
conﬁrmed histologically by use of videomediastinoscopy before
induction treatment. In patients with clinical stage IIIB T4, PET/
CT demonstrated several positive satellite nodes in the same
lobe in three patients and suspicion of inﬁltration of the superior
vena cava in two patients. All patients underwent induction
chemotherapy alone, consisting of a combination of platinum
(100 mg/m2) and gemcitabine (1000 mg/m2) in 13 patients and
of platinum and taxotere (85 mg/m2) in 18 patients. Stable
disease, partial and total remissions occurred in 9 (29%), 21
(68%) and 1 (3%) patients. The data of the pre- and post-
induction PET/CT examinations were reviewed in these 31
patients. Patient informed consent was obtained prior to surgery
for performing this analysis.
RESULTS
Restaging PET/CT revealed a new solitary focal abnormality in 6
of 31 (20%) patients after induction therapy. Characteristics of
these six patients, histology, clinical stage of the disease and
location of the primary are shown in Table 1. Induction
treatment could be completed in all patients. Transient neutro-
penia and gastroenteritis were observed in one patient.
In all patients, restaging PET/CT showed an important
decrease of the FDG uptake in the primary tumour as well as in
the mediastinal lymph nodes which were strongly PET positive
before induction treatment. Despite the small number of
patients, the decrease of maximal standard uptake value
(SUVmax) was signiﬁcant for the primary tumour (non-
parametric Wilcoxon test). Table 2 gives the values of SUVmax in
the primary and in the lymph nodes before and after induction
therapy. This radiological response to chemotherapy could be
conﬁrmed histopathologically by the presence of necrosis in the
operative specimen. Median necrosis values for the primary
tumour and for the lymph nodes were 45 and 20%, respectively.
The six new focal abnormalities revealed at restaging PET/CT
after induction chemotherapy were located in an ipsilateral cer-
vical lymph node in two patients, in the contralateral upper lobe
in two patients and in a contralateral paratracheal lymph node
and an ipsilateral mammary internal lymph node in one patient,
respectively (Table 3). These new PET-positive lesions showed a
high SUVmax, with a mean value of 5.8 ± 2.2. Diagnostic proce-
dures were carried out in ﬁve of six patients. Two patients
Table 2: Values of SUVmax before and after induction
treatment in the primary lung tumour and in the
mediastinal lymph nodes
Patient Primary tumour, SUVmax Mediastinal lymph nodes,
SUVmax
Pre-induction Post-induction Pre-induction Post-induction
1 7.3 2.7 6.6 0.1
2 10.7 4.4 8.4 3.8
3 7.9 4.8 4.3 2.8
4 16.8 6.4 16.7 3.2
5 10.4 1.2
6 9.6 5.7
P = 0.043a P = 0.068a
*aNon-parametric Wilcoxon test.
Table 3: Characteristics of the new focal abnormalities
revealed on restaging PET/CT after induction
chemotherapy
Patient New focal post-induction
abnormality (SUVmax)
Diagnostic
procedure
Diagnosis
1 Ipsilateral cervical LN (5.4) FNP Reactive LN
2 Ipsilateral cervical LN (7.2) FNP Reactive LN
3 Contralateral LN ATS 2L
(5.7)
Follow-up PET/
CT
Reactive LN
4 Contralateral LUL (3.8) Wedge resection
LUL
Pneumonia
5 Ipsilateral mammary
internal LN (3.1)
Intraoperative
resection
Reactive LN
6 Contralateral LUL (9.6) Wedge resection
LUL
Aspergilloma
LN, lymph node; LUL, left upper lobe; FNP, fine-needle puncture.
Table 1: Patient and tumour characteristics
Patient Gender Age
(years)
Histology cStage Location of the
primary
1 w 44 Adeno T1N2 Left upper lobe
2 m 61 Large cell T2N2 Left upper lobe
3 m 58 Squamous cell T2N2 Middle lobe
4 w 51 Adeno T2N2 Right upper lobe
5 m 62 Large cell T4N0 Left upper lobe
6 m 60 Squamous cell T4N1 Right lower lobe
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underwent a mini thoracotomy followed by a wedge resection
of the contralateral left upper lobe without postoperative com-
plication. Histopathological diagnosis revealed aspergilloma in
the ﬁrst (Fig. 1) and pneumonia in the second patient. Both
patients could undergo complete lung resection consisting of
right pneumonectomy and right upper lobectomy.
Two patients had preoperative ﬁne-needle punctures of
cervical lymph node (Fig. 2) and one had intraoperative resection
of a mammary internal lymph node. Histological/cytological
examination revealed benign reactive lymph nodes in all patients.
In the last patient, follow-up PET/CT at 1 month showed no focal
abnormality anymore and could exclude therefore tumour
involvement of the contralateral mediastinal lymph node.
DISCUSSION
In the 1990s, induction therapy, including preoperative radio-
chemotherapy or chemotherapy alone, has been increasingly
used for locally advanced stage III NSCLC in order to downstage
tumours and render them completely resectable [9, 10]. Several
studies have shown a strong survival beneﬁt in patients with
stage IIIA-N2 disease who have been down-staged by induction
therapy in comparison with patients with residual N2 disease
[1, 2]. It has also been shown that surgery can be carried out in a
curative intent in highly selected patients with stage IIIB-T4
disease within a multimodality therapy concept. The most im-
portant prognostic factors are complete resection and the
absence of mediastinal lymph node involvement. As a conse-
quence, accurate restaging after induction therapy is of para-
mount importance in these subgroups of patients. The difﬁculty
is to assess the pathological response after induction treatment.
In many centres restaging CT alone is carried out, despite its low
accuracy in restaging the mediastinum. Its sensitivity varied from
41 to 59% and its speciﬁcity from 75 to 62% with an accuracy of
58 and 60% [11, 12]. More invasive techniques such as endoeso-
phageal ultrasound-guided ﬁne-needle aspiration (EUS-FNA),
endobronchial ultrasound-guided transbronchial needle aspir-
ation (EBUS-TBNA) and mediastinoscopy offer the advantage of
providing cytological/histological evidence of response after in-
duction treatment. Until recently, these endoscopic techniques
have been studied fully in restaging N2 patients. In a pioneer
study, Annema and collaborators assessed the accuracy of
EUS-FNA for restaging the mediastinum after induction chemo-
therapy in 19 patients with proven N2 disease. The positive pre-
dictive value, negative predictive value, sensitivity, speciﬁcity and
Figure 1: A 60-year-old man with a central squamous cell carcinoma coming from the right lower lobe. (a) Axial PET/CT scan showed the high FDG primary
tumour before induction therapy. (b) Restaging axial PET/CT scan demonstrated the partial response of the primary tumour after induction therapy. (c) Restaging
axial PET/CT scan revealed the new solitary PET-positive lesion in the contralateral upper lobe. (d) Histopathology of the lung parenchyma FDG-positive lesion
revealed an aspergilloma.
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diagnostic accuracy of EUS-FNA in this small group of patients
were 100, 67, 75, 100 and 83%, respectively [13]. More recently,
Herth et al. published the results of a large trial evaluating
EBUS-TBNA in restaging the mediastinum after induction
chemotherapy in 124 patients with NSCLC. Overall sensitivity,
speciﬁcity, positive predictive value, negative predictive value
and diagnostic accuracy were 76, 100, 100, 20 and 77%, respect-
ively. Therefore, the authors recommended the need to conﬁrm
EBUS-FNA tumour-negative mediastinal nodes by surgical
staging before thoracotomy [14]. Repeated mediastinoscopy, al-
though technically more difﬁcult than the ﬁrst procedure due to
adhesions and mediastinal ﬁbrosis, is technically feasible in
experienced hands [15]. In different series, its sensitivity after in-
duction therapy for mediastinoscopy proven N2 disease was
reported from 70 to 78% except in one prospective study with a
reported sensitivity to detect mediastinal disease of 29% [11, 12,
16–18]. This low sensitivity was largely explained by the fact that
biopsy of the subcarinal nodes was not adequately carried out in
two of three of patients.
In our study, we used whole-body integrated PET/CT for
restaging in 31 patients. Accuracy of PET/CT was assessed in dif-
ferent settings related to induction protocol (chemotherapy or
chemoradiotherapy), timing of imaging (from 1 to 10 weeks post-
induction) and interpretation of imaging (visual or standardized
uptake value). Its sensitivity and speciﬁcity in three different
studies were 77 and 92%, 73 and 89% and 62 and 88%, respect-
ively [12, 19, 20]. Although accuracy of PET/CT in restaging is lower
than for staging untreated patients, it enables the direct correl-
ation of FDG-accumulating lesions with morphologic structures
throughout the body. It has also been shown that the comparison
of SUVmax values before and after induction treatment allowed
prediction of histopathological response in the primary tumour
and in the mediastinal lymph nodes, therefore carrying an
important prognostic value [19, 21]. In the present study, restaging
PET/CT showed a marked response in primary tumour
(P = 0.043) and in mediastinal nodes (P = 0.068) after induction
chemotherapy for all patients, indicating a favourable outcome.
Surprisingly, restaging PET/CT revealed new solitary high
FDG-positive lesions in cervical or contralateral mediastinal
lymph nodes as well as in the contralateral lung. There was a dis-
crepancy since FDG uptake had strongly decreased in the primary
and in the involved lymph nodes. The clinical signiﬁcance of
these new ﬁndings was unclear. Was it a metastasis or a second
tumour resistant to the induction treatment? Further manage-
ment of the patient would strongly differ according to the
neoplastic or inﬂammatory nature for the lesions. Cytological/
histopathological diagnosis was then mandatory. We carried out
preoperative ﬁne-needle punctures for cervical lymph nodes as
well as an intraoperative resection of the mammary interna
lymph node. These procedures revealed inﬂammatory reactive
lymph nodes. The same diagnosis could be deducted in a medi-
astinal contralateral lymph node from the disappearance of the
lesion’s high FDG-uptake on follow-up PET/CT. Regarding
FDG-positive lesions in the contralateral lung, histopathological
examination revealed an aspergilloma and pneumonia.
New solitary high FDG accumulation in lymph node or contra-
lateral parenchymal lung on restaging PET/CT after induction
chemotherapy in good responders with locally advanced NSCLC
were not rare (6 of 31 or 20%). In our experience, these
FDG-positive lesions did not imply progression of the disease
since they were diagnosed as benign lesions in all six patients.
Therefore, extensive diagnostic procedures for these lesions
could be avoided in the future if larger studies conﬁrm our
ﬁndings.
Figure 2: A 61-year-old man with a large-cell carcinoma of the left upper lobe and ipsilateral mediastinal lymph node invasion. (a) Axial PET/CT scan showed the
high FDG activity within the ipsilateral mediastinal lymph node. (b) Restaging axial PET/CT scan demonstrated the partial response of the mediastinal lymph node
after induction therapy. (c) Restaging axial PET/CT scan revealed the new solitary PET-positive lesion in the cervical lymph node. (d) Cytology after ﬁne-needle
puncture revealed a reactive lymph node.
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